Viral Vectors and Plasmid DNA Manufacturing Market Report 2025

This viral vectors and plasmid dna manufacturing market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The viral vectors and plasmid dna manufacturing market size has grown exponentially in recent years. It will grow from $5.75 billion in 2024 to $7.11 billion in 2025 at a compound annual growth rate (CAGR) of 23.8%. The growth in the historic period can be attributed to demand for personalized medicine, growth in vaccine development, availability of funding for gene therapy development, efficiency of viral vectors in gene therapy delivery, and potential applications in novel drug delivery approaches.

The viral vectors and plasmid dna manufacturing market size is expected to see exponential growth in the next few years. It will grow to $16.52 billion in 2029 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing number of gene therapies, growing number of market participants, increasing rates of infectious illnesses and hereditary abnormalities, increasing investments in cell and gene therapy research space, and growing occurrence of target disorders and diseases. Major trends in the forecast period include technological advancements, advancements in gene therapy, adoption of advanced technologies, adoption of single-use technologies, and advancement in vaccine technology.

The rising number of gene therapies is anticipated to boost the growth of the viral vectors and plasmid DNA manufacturing market. Gene therapy involves modifying genetic material within a person’s cells to treat or prevent disease. This field is advancing due to increased investment in biotechnology research and development and a deeper understanding of genetic and cellular mechanisms underlying various conditions. Viral vectors and plasmid DNA are crucial for delivering therapeutic genes into patients' cells, enabling the treatment of genetic disorders at a molecular level. For example, the American Society of Gene & Cell Therapy, a US-based non-profit organization, reported a 10% increase in the number of gene therapies in Phase III clinical trials during Q3 2023, marking the first quarterly rise since Q3 2022. This growth in gene therapies is driving demand for viral vectors and plasmid DNA manufacturing.

Key companies in the viral vectors and plasmid DNA manufacturing market are pursuing strategic partnerships to expand production capacities, enhance technological capabilities, and accelerate the global development and commercialization of gene therapies. These collaborations allow companies to share resources and infrastructure, boosting production capacity to meet the increasing demand for gene therapies. For instance, in June 2024, Charles River Laboratories International Inc., a US-based preclinical and clinical contract research organization, and Captain T Cell, a spin-off from Germany’s Max Delbrück Center, established a production program agreement for plasmid DNA and retrovirus vectors. This partnership grants Captain T Cell access to established contract development and manufacturing (CDMO) capabilities and advisory services, aiming to accelerate the progression from preclinical research to clinical trials for a novel TCR-T cell therapy targeting solid tumors.

In December 2023, Polyplus, a France-based biochemistry laboratory, acquired Xpress Biologics for an undisclosed amount. This acquisition is expected to enhance Polyplus' product portfolio and strengthen its capabilities in plasmid DNA production, which is vital for gene and cell therapies. Xpress Biologics, based in Belgium, specializes in producing plasmid DNA and proteins using microbial expression systems, and this acquisition will solidify Polyplus’ position in the expanding gene therapy market.

Major companies operating in the viral vectors and plasmid dna manufacturing market are Merck KGaA, Thermo Fisher Scientific Inc., Astellas Pharma Inc., Lonza Group AG, Catalent Inc., Revvity Inc., Wuxi Biologics Inc., BioMarin Pharmaceutical, FUJIFILM Diosynth Biotechnologies, Miltenyi Biotec GmbH, Aldevron LLC, Takara Bio Inc., Poseida Therapeutics Inc., RegenxBio Inc., Cobra Biologics, Finvector Vision Therapies Limited, Batavia Biosciences B.V., uniQure N.V., Addgene Inc., BioNTech IMFS GmbH, Creative Biogene Inc., Genezen Laboratories Inc., Virovek Incorporation, Waisman Biomanufacturing, Axplora GmbH.

North America was the largest region in the viral vectors and plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the viral vectors and plasmid dna manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the viral vectors and plasmid dna manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Viral vectors and plasmid DNA manufacturing involves the production of viral vectors and plasmid DNA, which are crucial for gene therapy, vaccine development, and genetic research. This process includes complex biotechnological techniques to ensure the safety, efficacy, and consistency of the products.

Key products in the viral vectors and plasmid DNA manufacturing market include plasmid DNA, viral vectors, and non-viral vectors. Plasmid DNA consists of small, circular DNA molecules utilized in genetic research and biotechnology. These products are manufactured at various scales - preclinical, clinical, and commercial. The market addresses a range of therapeutic areas, including oncology, rare diseases, neurological and sensory disorders, metabolic and musculoskeletal disorders, blood disorders, and immunological disorders. These products are used in gene therapies, cell therapies, and vaccines. Manufacturing is conducted by both in-house teams and contract manufacturing organizations (CMOs).

The viral vectors and plasmid DNA manufacturing market research report is one of a series of new reports that provides viral vectors and plasmid DNA manufacturing market statistics, including the viral vectors and plasmid DNA manufacturing industry global market size, regional shares, competitors with viral vectors and plasmid DNA manufacturing market share, detailed viral vectors and plasmid DNA manufacturing market segments, market trends, and opportunities, and any further data you may need to thrive in the viral vectors and plasmid DNA manufacturing industry. These viral vectors and plasmid DNA manufacturing market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The viral vectors and plasmid DNA manufacturing market consists of revenues earned by entities by providing services such as process development, cell line development, and analytical and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. The viral vectors and plasmid DNA manufacturing market also includes sales of bioreactors, cell culture systems, reagents and consumables. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.